2022
A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients’ Five-Tier Rating System
Wang K, Deng Y, Stewart D, Formica R. A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients’ Five-Tier Rating System. Journal Of The American Society Of Nephrology 2022, 33: 1613-1624. PMID: 35537779, PMCID: PMC9342646, DOI: 10.1681/asn.2022010078.Peer-Reviewed Original ResearchConceptsComposite end pointTraditional end pointsTransplant programsEnd pointAllograft functionGraft survivalScientific RegistryFive-tier systemLong-term graft outcomeDonor graft survivalKidney transplant programAllograft failureAllograft survivalGraft outcomeTransplant recipientsGraft statusGraft failureEGFR differenceSRTR dataSurvival rateEGFRSurvivalRegistryMeaningful differencesConcept study
2004
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period
Formica RN, Friedman AL, Lorber MI, Bia MJ. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period. Transplantation Proceedings 2004, 36: 2675-2678. PMID: 15621121, DOI: 10.1016/j.transproceed.2004.10.013.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersEarly posttransplant periodII receptor blockersCalcium channel blockersTreatment of hypertensionPosttransplant periodReceptor blockersEnzyme inhibitorsAcute renal dysfunctionAdministration of ACEAdult renal transplantsAppropriate clinical criteriaRenal transplant patientsGlomerular filtration rateType of transplantUse of ACESerum potassium concentrationAllograft functionPancreas transplantsRenal dysfunctionRenal transplantTransplant patientsSerum creatininePosttransplant erythrocytosisSerum potassium